Ranbaxy Laboratories Ltd (Ranbaxy) announced today that the World Health Organisation, Geneva (WHO), has included the Company's Indinavir (as sulfate) - 400mg Anti Retroviral (ARV) Capsule, in its pre-qualification list. With this new addition, Ranbaxy now has a total of 19 ARVs on the WHO pre-qualification list.
Commenting on the WHO listing, Ranbaxy's CEO & MD, Mr. Atul Sobti said, "Ranbaxy remains committed to provide high quality affordable generic ARV medicines and will continue to dedicate itself in fighting the worldwide struggle against HIV / AIDS. Ranbaxy's ARVs, including the recently approved WHO pre-qualified products, are manufactured at the Company's state-of-the-art manufacturing facilities."
Since 2001, Ranbaxy has been providing high quality ARV medicines, at affordable prices, in over 70 markets worldwide, thereby facilitating access to patients afflicted by HIV / AIDS who might not otherwise have been able to gain access to this therapy. The Company's ARVs have been used as mainstays in various large treatment programs, both National and NGO / Institutional with good results. ARV medicine produced by Ranbaxy are used by over 400000 patients worldwide, in various developing and underdeveloped countries.
Ranbaxy is committed to supporting the global fight against HIV / AIDS through high quality, affordable medicines.
The stock closed the day at Rs.412.30, down by Rs.0.60 or 0.15%. The stock hit an intraday high of Rs.418.75 and low of Rs.408.
The total traded quantity was 700432 at an average price of Rs 413.16.
|
